author-photo

Emilie M.J. van Brummelen

Netherlands Cancer Institute

24

Papers

1302

Citations

Citation Trend

Filter By

Papers (24) Sort By

Journal Conference Others

Phase 1 clinical trial of losmapimod in facioscapulohumeral dystrophy: Safety, tolerability, pharmacokinetics, and target engagement

2021 British Journal of Clinical Pharmacology
Show All
- Source
- Cite
- Save
Citations (0)
Healthy Volunteers in First in Human Oncology Drug Development for Small Molecules.

2021 British Journal of Clinical Pharmacology
Show All
- Source
- Cite
- Save
Citations (0)
First-in-human trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of STR-324, a dual enkephalinase inhibitor for pain management.

2021 British Journal of Clinical Pharmacology
Show All
- Source
- Cite
- Save
Citations (0)
Quantification of tremor using consumer product accelerometry is feasible in patients with essential tremor and Parkinson's disease: a comparative study.

2020
Show All
- Source
- Cite
- Save
Citations (4)
Phase I Study of Afatinib and Selumetinib in Patients with KRAS‐Mutated Colorectal, Non‐Small Cell Lung, and Pancreatic Cancer

2020 Oncologist
Show All
- Source
- Cite
- Save
Citations (4)
Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer.

2020 Cancer Chemotherapy and Pharmacology
Show All
- Source
- Cite
- Save
Citations (12)
Phase 1 Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD): Safety, Tolerability, and Target Engagement (1557)

2020 Neurology
Show All
- Source
- Cite
- Save
Citations (1)
First-in-human administration of a live-attenuated RSV vaccine lacking the G-protein assessing safety, tolerability, shedding and immunogenicity: a randomized controlled trial

2020 Vaccine
Show All
- Source
- Cite
- Save
Citations (4)
Phase I study of afatinib plus selumetinib in patients with KRAS mutation-positive colorectal, non-small cell lung and pancreatic cancer.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS- mutation-positive colorectal, non-small-cell lung and pancreatic cancer

2020 British Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (10)